Saturday, October 14, 2023 2:06:56 PM
Flipper, I believe you're right on the money. I believe we'll have trials beginning that are co-sponsored by BP's, but I believe they want to do it when DCVax-L is an approved product in at least one venue. At that time I believe that the BP partner can properly pay for the vaccine they're using in the trial, before that time I think NWBO would have to contribute the vaccine. No doubt the BP will get a discount, and that might be all that constituted NWBO's contribution to being in the trial. These trials could be more meaningful to the BP as they'll add to their label. Most of the patients would be getting treatment with DCVax-L anyway.
I believe that once approved, anyone should be able to purchase DCVax-L for use in a trial. If NWBO agrees to reduce the purchase price, they become a co-sponsor even if they're profiting from every patient dosed in the trial.
I'm not saying that every trial will be structured this way, but I believe we could have at least a few of them.
Gary
I believe that once approved, anyone should be able to purchase DCVax-L for use in a trial. If NWBO agrees to reduce the purchase price, they become a co-sponsor even if they're profiting from every patient dosed in the trial.
I'm not saying that every trial will be structured this way, but I believe we could have at least a few of them.
Gary
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
